German cosmetic ingredient developer Cambrium has published the results of efficacy testing for its first product, NovaColl.
Launched in March, NovaColl is claimed to be the first micro-molecular and 100% skin-identical, vegan collagen specifically designed for premium personal care formulations.
Ex vivo testing of the topical skincare ingredient was conducted by a third party using human skin explants, which were treated with NovaColl and measured for density of the collagen matrix; expression levels of collagenase (enzymes which break down collagen); and the synthesis of procollagen 1 (the precursor to collagen) and collagen 1.
"Our molecular design technology enables us to achieve unprecedented material performance," said Cambrium head of R&D Lucile Bonnin.
“We are very pleased that this data supports the unique ‘protect, maintain, and enhance’ claim for NovaColl,” she added.
The results of these studies, available from Cambrium upon request, corroborate previous third party in vitro studies that demonstrated broad activities to holistically protect, maintain and enhance native collagen.
Cambrium was founded by Dr. Mitchell James Duffy and Dr. Charlie Cotton in 2020, and is backed by investors including Merantix.
Further efficacy studies for NovaColl are in progress, the Berlin company said.